Grails

ICONIC MOMENTS PARTNERS WITH WHITE HOUSE HISTORICAL ASSOCIATION TO PRODUCE NFT ART FOR PROOF COLLECTIVE'S GRAILS II RELEASE

Retrieved on: 
Thursday, August 25, 2022
Linda, Partnership, CEO, Female, Artificial intelligence, Awareness, White House, Resurrection, White House Historical Association, Ownership, Art in the White House, Culture, Lifting, Sun, Monty Python and the Holy Grail Collectible Card Game, Collection, White, Senior, Executive Mansion (Virginia), Storytelling, Multimedia, Non-fungible token, Official, WHHA, NFT, Grails, History, Museum, Association, Industry, Sparrow, Cryptocurrency, Interior design

Iconic Moments is the first NFT platform focused on bringing stories and history to life for Iconic brands & cultural institutions.

Key Points: 
  • Iconic Moments is the first NFT platform focused on bringing stories and history to life for Iconic brands & cultural institutions.
  • https://iconicmoments.co/
    About The White House Historical Association:
    First Lady Jacqueline Kennedy envisioned a restored White House that conveyed a sense of history through its decorative and fine arts.
  • In 1961, the nonprofit, nonpartisan White House Historical Association was established to support her vision to preserve and share the Executive Mansion's legacy.
  • Since its founding, the Association has given more than $50 million to the White House in fulfillment of its mission.

GRAIL, AccessHope Collaborate to Optimize Patient and Healthcare Provider Experience for Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

Retrieved on: 
Tuesday, March 16, 2021
Cardiology, Biotechnology, Practice Management, Medical Supplies, Oncology, General Health, Health, Medical devices, Medical terminology, Cancer, Medicine, Grails, Medical diagnosis, Branches of biology, Health care, GRAIL, AccessHope

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today it is joining forces with AccessHope to offer a world-class service experience to people who use Galleri, GRAILs first-of-kind multi-cancer early detection blood test.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today it is joining forces with AccessHope to offer a world-class service experience to people who use Galleri, GRAILs first-of-kind multi-cancer early detection blood test.
  • AccessHope also will provide support to physicians as they determine next steps to evaluate a positive Galleri test result.
  • Best-in-class expert services like those offered by AccessHope will be an essential part of GRAIL supporting providers and their patients from test to diagnosis to treatment.
  • AccessHope serves more than 2 million members who have cancer support benefits through 42 employers, including 18 Fortune 500 companies.

GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test

Retrieved on: 
Tuesday, March 2, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Medicine, Medical terminology, Cancer, Screening, Grails, Health sciences, Health, GRAIL, Providence

Providence, based in Renton, Washington, will be the first health system to offer Galleri, GRAILs multi-cancer early detection blood test, as a complement to recommended single cancer screening tests.

Key Points: 
  • Providence, based in Renton, Washington, will be the first health system to offer Galleri, GRAILs multi-cancer early detection blood test, as a complement to recommended single cancer screening tests.
  • The blood test, which will be prescription only, will be available initially through partner health systems, medical practices, and self-insured employers.
  • GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.
  • Providence is a national, not-for-profit Catholic health system comprising a diverse family of organizations and driven by a belief that health is a human right.

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

Retrieved on: 
Monday, January 11, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Companies, Life sciences, Health sciences, Leukemia, Minimal residual disease, Amgen, AstraZeneca, Bristol Myers Squibb, Grails, Cancer

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAILs methylation-based technology for the detection of minimal residual disease (MRD).

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAILs methylation-based technology for the detection of minimal residual disease (MRD).
  • Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual disease.
  • Cancer never quits, making the detection of residual disease and early recurrences critical to helping patients and care providers stay ahead of the disease.
  • GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.

Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Care

Retrieved on: 
Thursday, August 6, 2020
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Health, Pharmaceutical industry, Clinical research, Clinical pharmacology, Design of experiments, Investigational device exemption, Grails, Food and Drug Administration, Clinical trial, Cleveland Clinic, the PATHFINDER Study, GRAIL

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today that Cleveland Clinic has joined GRAILs PATHFINDER Study, a prospective, multi-center clinical study that is evaluating the implementation of Galleri, an investigational multi-cancer early detection blood test, into clinical practice for the first time.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today that Cleveland Clinic has joined GRAILs PATHFINDER Study, a prospective, multi-center clinical study that is evaluating the implementation of Galleri, an investigational multi-cancer early detection blood test, into clinical practice for the first time.
  • Cleveland Clinic joins initial PATHFINDER health system partners that include Dana-Farber Cancer Institute, Intermountain Healthcare, Mayo Clinic, Oregon Health & Science University, and Sutter Health.
  • The PATHFINDER Study is conducted under an investigational device exemption (IDE) application approved by the Food and Drug Administration (FDA) to evaluate GRAILs multi-cancer early detection test.
  • The PATHFINDER Study is evaluating the implementation of GRAILs investigational multi-cancer early detection test in clinical practice, and marks the first time Galleri will be used to return results to people.

GRAIL Announces $390 Million Series D Financing

Retrieved on: 
Wednesday, May 6, 2020
Biotechnology, Pharmaceutical, Health, Oncology, RTT, Cancer, Grails, Holy Grail, Christianity, Literature, Legends, GRAIL’s Multi-Cancer Early Detection Test, GRAIL

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round.
  • GRAIL is making significant progress with our blood-based, multi-cancer early detection test, said Hans Bishop, Chief Executive Officer at GRAIL.
  • The Series D funding adds to the companys balance sheet and will support continued development and commercialization of GRAILs multi-cancer early detection blood test.
  • Since early 2016, GRAIL has raised more than $1.9 billion in four rounds of equity financing to pursue reducing cancer mortality worldwide through multi-cancer early detection.

GRAIL Appoints Satnam Alag as Senior Vice President of Software Engineering

Retrieved on: 
Wednesday, April 29, 2020
Oncology, Health, Technology, Genetics, Software, Biotechnology, Microarrays, Computing, Lumi, Grails, Illumina, Inc., Biotechnology, Biology

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Satnam Alag, PhD, as Senior Vice President of Software Engineering.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Satnam Alag, PhD, as Senior Vice President of Software Engineering.
  • In his new role, Dr. Alag will be responsible for providing the leadership, strategic vision, and operational execution for GRAILs software teams.
  • Dr. Alag joins GRAIL from Illumina, where he most recently served as Vice President of Software Engineering, Product Development.
  • Dr. Alag has also served in other senior software architecture positions, including as the Chief Software Architect at Deem.

GRAIL Appoints Sir Harpal Kumar as President of GRAIL Europe

Retrieved on: 
Friday, April 10, 2020
Oncology, Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Harpal, Relics associated with Jesus, Grails, Holy Grail, Cancer, Christianity, Literature, Legends

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Sir Harpal Kumar as President of GRAIL Europe.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Sir Harpal Kumar as President of GRAIL Europe.
  • In this new role, Sir Harpal will be responsible for leading GRAILs entry and growth in Europe.
  • I'm thrilled to be joining GRAIL and to have the opportunity to transform cancer care through early detection, said Sir Harpal.
  • Sir Harpal joins GRAIL from Johnson & Johnson where he most recently served as Senior Vice President and Head of Innovation EMEA.

GRAIL Initiates First Interventional Study Using its Multi-Cancer Early Detection Test to Guide Clinical Care

Retrieved on: 
Tuesday, February 18, 2020
Biotechnology, FDA, Health, Clinical trials, Oncology, Pharmaceutical industry, Investigational device exemption, Grails, the PATHFINDER Study, GRAIL

GRAIL is at the forefront of transforming early cancer detection as we bring our multi-cancer test into clinical practice through our first interventional study, said Hans Bishop, Chief Executive Officer at GRAIL.

Key Points: 
  • GRAIL is at the forefront of transforming early cancer detection as we bring our multi-cancer test into clinical practice through our first interventional study, said Hans Bishop, Chief Executive Officer at GRAIL.
  • The PATHFINDER Study is conducted under an investigational device exemption (IDE) to evaluate GRAILs multi-cancer early detection test.
  • The PATHFINDER Study is evaluating the implementation of GRAILs investigational multi-cancer early detection test in clinical practice, and marks the first time GRAILs test will be used to return results to people.
  • PATHFINDER is being conducted under an FDA approval of an IDE application for GRAILs multi-cancer early detection blood test.

GRAIL Announces Positive Validation Data for Its Multi-Cancer Early Detection Test

Retrieved on: 
Monday, October 7, 2019
Medical devices, Genetics, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, RTT, Cancer, Grails, Biology, Molecular biology, Life sciences, Medical genetics, Biotechnology, Medical devices, Genetics, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, RTT, Cancer, Grails, Biology, Molecular biology, Life sciences, Medical genetics, Biotechnology, CCGA, GRAIL’s Investigational Multi-Cancer Early Detection Test, GRAIL

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced new data validating the performance of its investigational multi-cancer early detection blood test for the first time in an independent cohort of participants.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced new data validating the performance of its investigational multi-cancer early detection blood test for the first time in an independent cohort of participants.
  • GRAILs large-scale clinical study program is designed to train and develop a multi-cancer early detection test, as well as validate its performance.
  • Performance in the validation analysis was consistent with previously reported results from data used to train GRAILs cancer detection algorithm to classify cancer and non-cancer signals.
  • GRAIL is developing a next-generation sequencing (NGS) blood test for the early detection of multiple deadly cancer types.